日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Plasmodiumfalciparum protein kinase 6 and hemozoin formation are inhibited by a type II human kinase inhibitor exhibiting antimalarial activity

一种具有抗疟活性的II型人激酶抑制剂可抑制恶性疟原虫蛋白激酶6和血红素的形成。

Flore Nardella ,Tiantian Jiang ,Lushun Wang ,Monica J Bohmer ,Subhoja Chakraborty ,John Okombo ,Jaeson Calla ,Tatiane Macedo Silva ,Samuel Pazicky ,Jianwei Che ,Jin Jeon ,Evie Vincent ,Nonlawat Boonyalai ,Rachael Coyle ,Mairi J Buchanan ,Samuel Schaefer ,Daisy Chen ,Amaan Khan ,Emily Mayville ,Mariana Laureano De Souza ,Mayland Treat ,Jordan Charlton ,Patrick K Tumwebaze ,Seth Tjia ,Lukas Montejo ,Karen Cover ,Philip J Rosenthal ,Roland A Cooper ,Zbynek Bozdech ,Marcus C S Lee ,Ratna Chakrabarti ,Sanjay A Desai ,David A Fidock ,Jinhua Wang ,Nathanael S Gray ,Elizabeth A Winzeler ,Debopam Chakrabarti

The plasmepsin-piperaquine paradox persists in Plasmodium falciparum.

恶性疟原虫中持续存在血浆蛋白酶-哌喹悖论

Walsh Breanna, Summers Robert L, Rangel Gabriel W, Hagenah Laura M, Mok Sachel, Llinás Manuel, Fidock David A, Wirth Dyann F, Bopp Selina

Quinoxaline-based anti-schistosomal compounds have potent anti-plasmodial activity.

喹喔啉类抗血吸虫化合物具有很强的抗疟原虫活性

Rawat Mukul, Padalino Gilda, Adika Edem, Okombo John, Yeo Tomas, Brancale Andrea, Fidock David A, Hoffmann Karl F, Lee Marcus C S

Recombinant proteasome provides new avenues for anti-malarial drug development.

重组蛋白酶体为抗疟药物的研发提供了新的途径

Fajtova Pavla, Zhang Hanxiao, Urich Liam, da Silva Elany Barbosa, da Silva Cesar Hoffmann, Almaliti Jehad, Al-Hindy Momen, Boura Evzen, Fidock David A, Kirkman Laura A, Lin Gang, Bogyo Matthew, Gerwick William H, Zhao Jianhua, O'Donoghue Anthony J

Systematic in vitro evolution in Plasmodium falciparum reveals key determinants of drug resistance.

恶性疟原虫体外系统进化揭示了耐药性的关键决定因素

Luth Madeline R, Godinez-Macias Karla P, Chen Daisy, Okombo John, Thathy Vandana, Cheng Xiu, Daggupati Sindhu, Davies Heledd, Dhingra Satish K, Economy Jan M, Edgar Rebecca C S, Gomez-Lorenzo Maria G, Istvan Eva S, Jado Juan Carlos, LaMonte Gregory M, Melillo Bruno, Mok Sachel, Narwal Sunil K, Ndiaye Tolla, Ottilie Sabine, Palomo Diaz Sara, Park Heekuk, Peña Stella, Rocamora Frances, Sakata-Kato Tomoyo, Small-Saunders Jennifer L, Summers Robert L, Tumwebaze Patrick K, Vanaerschot Manu, Xia Guoqin, Yeo Tomas, You Ashley, Gamo Francisco-Javier, Goldberg Daniel E, Lee Marcus C S, McNamara Case W, Ndiaye Daouda, Rosenthal Philip J, Schreiber Stuart L, Serra Gloria, De Siqueira-Neto Jair Lage, Skinner-Adams Tina S, Uhlemann Anne-Catrin, Kato Nobutaka, Lukens Amanda K, Wirth Dyann F, Fidock David A, Winzeler Elizabeth A

Determinants of piperaquine-resistant malaria in South America

南美洲哌喹耐药疟疾的决定因素

Mok, Sachel; Fidock, David A

tRNA modification reprogramming contributes to artemisinin resistance in Plasmodium falciparum

tRNA 修饰重编程导致恶性疟原虫产生青蒿素耐药性

Jennifer L Small-Saunders, Ameya Sinha, Talia S Bloxham, Laura M Hagenah, Guangxin Sun, Peter R Preiser, Peter C Dedon, David A Fidock

Inhibitors of malaria parasite cyclic nucleotide phosphodiesterases block asexual blood-stage development and mosquito transmission.

疟原虫环核苷酸磷酸二酯酶抑制剂可阻断无性血液期发育和蚊子传播

Gomez-Gonzalez Paula-Josefina, Gupta Antima, Drought Laura G, Patel Avnish, Okombo John, van der Watt Mariëtte, Walker-Gray Ryan, Schindler Kyra A, Burkhard Anna Y, Yeo Tomas, Narwal Sunil K, Bloxham Talia S, Flueck Christian, Walker Eloise M, Rey Joshua A, Fairhurst Kate J, Reader Janette, Park Heekuk, Pollard Harry G, Stewart Lindsay B, Brandner-Garrod Luke, Kristan Mojca, Sterk Geert-Jan, van Nuland Youri M, Manko Emilia, van Schalkwyk Donelly A, Zheng Yang, Leurs Rob, Dechering Koen J, Aguiar Anna Caroline C, Guido Rafael V C, Pereira Dhelio B, Tumwebaze Patrick K, Nosbya Samuel L, Rosenthal Philip J, Cooper Roland A, Palmer Mike, Parkinson Tanya, Burrows Jeremy N, Uhlemann Anne-Catrin, Birkholtz Lyn-Marié, Small-Saunders Jennifer L, Duffy James, Fidock David A, Brown Alan, Gardner Mark, Baker David A

Identification of potent and reversible piperidine carboxamides that are species-selective orally active proteasome inhibitors to treat malaria.

鉴定出强效且可逆的哌啶甲酰胺类化合物,它们是具有物种选择性的口服活性蛋白酶体抑制剂,可用于治疗疟疾

Lawong Aloysus, Gahalawat Suraksha, Ray Sneha, Ho Nhi, Han Yan, Ward Kurt E, Deng Xiaoyi, Chen Zhe, Kumar Ashwani, Xing Chao, Hosangadi Varun, Fairhurst Kate J, Tashiro Kyuto, Liszczak Glen, Shackleford David M, Katneni Kasiram, Chen Gong, Saunders Jessica, Crighton Elly, Casas Arturo, Robinson Joshua J, Imlay Leah S, Zhang Xiaoyu, Lemoff Andrew, Zhao Zhiyu, Angulo-Barturen Iñigo, Jiménez-Díaz María Belén, Wittlin Sergio, Campbell Simon F, Fidock David A, Laleu Benoît, Charman Susan A, Ready Joseph M, Phillips Margaret A

Mixed alkyl/aryl phosphonates identify metabolic serine hydrolases as antimalarial targets

混合烷基/芳基膦酸酯可识别代谢丝氨酸水解酶作为抗疟靶点

John M Bennett ,Sunil K Narwal ,Stephanie Kabeche ,Daniel Abegg ,Vandana Thathy ,Fiona Hackett ,Tomas Yeo ,Veronica L Li ,Ryan Muir ,Franco Faucher ,Scott Lovell ,Michael J Blackman ,Alexander Adibekian ,Ellen Yeh ,David A Fidock ,Matthew Bogyo